• IDT awarded 5-year contract to manufacture NPI-001 for Nacuity Pharmaceuticals
• NPI-001 is an investigational treatment for retinitis pigmentosa, a progressive eye disease
• IDT will recommission its 4,000L API plant, making it the largest small molecule API facility in Australia

IDT Australia Limited (ASX: IDT) has announced that it has been awarded a five-year contract for the current Good Manufacturing Practice (cGMP) manufacture of NPI-001 (N-acetylcysteine amide) tablets - a new and innovative investigational therapy for the treatment of patients with retinitis pigmentosa (RP). The agreement, awarded by Nacuity Pharmaceuticals Pty Ltd, includes an initial statement of work for $3.2M, which is expected to conclude at the end of FY2026, and allows for annual follow up contracts. The project will be executed at IDT's 4,000L cGMP manufacturing plant, which has been recommissioned for this initiative. This plant will be the largest small molecule Active Pharmaceutical Ingredient (API) facility in Australia and will present a strategic advantage for addressing potential drug shortage opportunities and other large scale API manufacturing needs. Nacuity Pharmaceuticals received FDA Fast Track designation for RP, a progressive degenerative eye disease with no standard treatment that leads to vision loss. The NPI-001 program has achieved this designation, recognizing its potential to address an unmet medical need for a serious disease and expedite its development and regulatory review. Manufacturing activities for the NPI-001 project are already underway and are scheduled for completion by the end of the calendar year. This contract represents a significant milestone in IDT's strategy to expand its pharmaceutical manufacturing capabilities and leverage its expertise in the production of groundbreaking therapies.

The recommissioned 4,000L API plant will give IDT a strategic advantage for addressing potential drug shortages and other large-scale API manufacturing needs in Australia.